Penbutolol in hypertension: evaluation of a new beta-adrenergic blocking drug.
The hypotensive effect of penbutolol, a new beta-adrenergic blocking drug, has been evaluated in a doulbe-blind crossover trial on 15 patients. Blood pressures were significantly lower during active drug treatment (P less than 0.001), the average reduction being: 1.7/0.9 kPa (13/7 mmHg) erect.